Search Result
15 search results for Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms
NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfErdheim-Chester Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfLangerhans Cell Histiocytosis
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfRosai-Dorfman Disease
NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfTransparency Process
: 2.2024 ( Uterine Neoplasms ) Date: 2024-02-29 Meeting Evidence Panel Disclosures/Attendance, : 1.2024 ( Uterine Neoplasms ) Date: 2023-06-30 Meeting Evidence Panel Disclosures, Panel Disclosures/Attendance Version: 2.2023 ( Uterine Neoplasms ) Date: 2023-04-07 Meeting Evidence Panel Disclosures/Attendance Version: 2.2023 ( Uterine Neoplasms, Version: 1.2023 ( Uterine Neoplasms ) Date: 2022-11-14 Meeting Evidence Panel
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsPermission to Cite or Use NCCN Content
Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening, Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Malignant Pleural, Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Transplantation Hematopoietic Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma, Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Management of Immunotherapy
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentRecently Updated Guidelines
Hepatocellular Carcinoma Version 2.2024 Histiocytic Neoplasms Version 2.2024 Kidney
https://www.nccn.org/guidelines/recently-published-guidelinesGuidelines Panels
Cancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsTreatment by Cancer Type
Version: 2.2024 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 2.2024 Myeloproliferative Neoplasms, Neoplasms Version: 2.2024 Vaginal Cancer
https://www.nccn.org/guidelines/category_1Submission Request Form
Growth Factors - 3.2024 Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 2.2024 Histiocytic Neoplasms - 2.2024 Hodgkin Lymphoma - 3.2024 Kaposi Sarcoma - 1.2024 Kidney Cancer - 1.2025 Lung, - 2.2024 Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 2.2024 Myeloproliferative Neoplasms - 1.2024 Neuroblastoma - 2.2024 Neuroendocrine and Adrenal Tumors - 1.2024, Thyroid Carcinoma - 3.2024 Uterine Neoplasms - 2.2024 Vaginal Cancer - 1.2025 Vulvar Cancer - 4.2024
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formResume Screening
Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer, Fungoides/Sézary Syndrome Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal
https://www.nccn.org/covid-19/resume-screeningGuidelines With Evidence Blocks
Version 4.2024 Hepatocellular Carcinoma Version 1.2024 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 Myeloproliferative Neoplasms Version 1.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 3.2024 Uterine Neoplasms Version 2.2024
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksChemotherapy Order Templates Reviewer Acknowledgement
Roswell Park Comprehensive Cancer Center Histiocytic Neoplasms, Moffitt Cancer Center Myeloid/Lymphoid Neoplasms, Fox Chase Cancer Center Myeloproliferative Neoplasms, University of Michigan Rogel Cancer Center Uterine Neoplasms
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementSubmission Request History
on 10/17/2019 Nivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020, . on 04/29/2020 Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline, Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyAnnual Report 2023
neoplasms. These clinical resources were also translated into Chinese by leading experts in the region
https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31